User menu

Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a

Bibliographic reference Jongen, Peter Joseph ; Sindic, Christian ; Carton, Herwig ; Zwanikken, Cees ; Lemmens, Wim ; et. al. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. In: Journal of Neurology : official journal of the European Neurological Society, Vol. 257, no. 4, p. 584-589 (2010)
Permanent URL http://hdl.handle.net/2078.1/33990
  1. Arnoldus JH, Killestein J, Pfennings LE, Jelles B, Uitdehaag BM, Polman CH (2000) Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler 6:338–342
  2. Cohen J. A., Fischer J. S., Bolibrush D. M., Jak A. J., Kniker J. E., Mertz L. A., Skaramagas T. T., Cutter G. R., Intrarater and interrater reliability of the MS functional composite outcome measure, 10.1212/wnl.54.4.802
  3. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Jak AJ et al (2001) Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58:961–967
  4. Cutter G, Baier M, Rudick RA, Cookfair DL, Fischer JS, Petkau J et al (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122:871–882
  5. Hopman Wilma M., Coo Helen, Edgar Cathy M., McBride Evelyn V., Day Andrew G., Brunet Donald G., Factors Associated with Health-Related Quality of Life in Multiple Sclerosis, 10.1017/s0317167100005989
  6. International Conference on Harmonisation (1997) Federal Register 62:52239–52245
  7. Lily O, McFadden E, Hensor E, Johnson M, Ford H (2006) Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler 12:808–813
  8. Miller DM, Rudick RA, Baier M, Cutter G, Dougherty DS, Weinstock-Guttman B et al (2003) Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Mult Scler 9:1–5
  9. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS (2000) Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life. Arch Neurol 57:1319–1324
  10. Ozakbas S, Cagiran I, Ormeci B, Idiman E (2004) Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after relapses in patients with multiple sclerosis. J Neurol Sci 218:1–2
  11. Pfaffenberger N, Pfeiffer K-P, Deibl M, Hoefer S, Guenther V, Ulmer H (2006) Association of factors influencing health-related quality of life in MS. Acta Neurol Scand 114:102–108
  12. Rice G.P., Oger J., Duquette P., Francis G.S., Bélanger M., Laplante S., Grenier J.F., Treatment with Interferon Beta-1b Improves Quality of Life in Multiple Sclerosis, 10.1017/s031716710000038x
  13. Simone IL, Ceccarelli A, Tortorella C, Bellacosa A, Pellegrini F, Plasmati I et al (2006) Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes 12:96
  14. Vermersch P, de Seze J, Delisse B, Lemaire S, Stojkovic T (2002) Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment. Mult Scler 8:377–381
  15. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW (1995) A health-related quality of life measure for multiple sclerosis. Qual Life Red 4:187–206
  16. Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin L et al (2003) A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci 216:113–118